進階搜尋


   電子論文尚未授權公開,紙本請查館藏目錄
(※如查詢不到或館藏狀況顯示「閉架不公開」,表示該本論文不在書庫,無法取用。)
系統識別號 U0026-0108201817195500
論文名稱(中文) 非熱微電漿對惡性黑色素瘤細胞的存活之探討
論文名稱(英文) A Cell Viability Study of Non-Thermal Micro-Plasma Exposure on Malignant Melanoma Cells
校院名稱 成功大學
系所名稱(中) 材料科學及工程學系
系所名稱(英) Department of Materials Science and Engineering
學年度 106
學期 2
出版年 107
研究生(中文) 吳彥緯
研究生(英文) Han Wu
學號 N56055047
學位類別 碩士
語文別 英文
論文頁數 73頁
口試委員 指導教授-廖峻德
共同指導教授-劉浩志
共同指導教授-王士豪
口試委員-邵佩琳
中文關鍵字 非熱微電漿  抗癌  抑制癌細胞生長  電漿激活培養基 
英文關鍵字 Non-thermal micro-plasma  plasma activated medium  anti-cancer effect 
學科別分類
中文摘要 最近的研究已經證明,非熱微電漿(NTP)可以使癌細胞失去活性,並且對人體只有很小的副作用。 NTP是部分電離的氣體屬於物質的第四態,其是含有中性原子,電子和離子的能量粒子。以往NTP是直接照射於癌細胞或腫瘤,但可以照射的受傷面積和深度有限。因此近幾年研究了一種新的間接照射的方法,稱為Plasma Activated Medium(PAM)。 PAM方法是只有細胞培養基暴露於NTP,任何直接的NTP射線到目標細胞都排除掉,之後將處理過後的細胞培養基提供給目標細胞或是以注射的方式打到腫瘤中。PAM被證實具有與直接照射有著相同的抗癌作用,最重要的是PAM可以忽略暴露深度限制並覆蓋NTP無法實現的較大受傷區域例如腫瘤。然而PAM的抗癌細胞能力不如直接照射來的有效,但究竟是多低仍然未知,因此在本研究中,PAM的能力將通過使用直接照射作為參考與PAM比較後得到確認。本研究中使用了惡性黑色素瘤細胞B16-F10,A375和MeWo細胞,惡性黑色素瘤是最危險的皮膚癌細胞類型,選擇皮膚癌作為目標細胞的原因是由於惡性黑色素瘤可通過直接照射或PAM輕易獲得。實驗結果PAM的效果僅略低於直接照射。此外NTP對B16-F10和MeWo細胞有很大影響。另一方面A375細胞則表現出對NTP有極強的抗性。PAM是一種新的電漿方法,它有很大的淺力可以成為未來皮膚癌治癒的新選擇。
英文摘要 Recent researches have proven that non-thermal micro-plasma (NTP) can inactivate cancer cells with low side effects to the human body. NTP is a gas that ionized partially which contain energy particles including neutral atoms, electrons, and ions. Previously NTP was directly applied to cells or tumors but the injured area and depth is limited; hence, a new indirect plasma exposure method was investigated which known as Plasma Activated Medium (PAM). The PAM method means only medium was exposed to NTP any direct exposure from NTP to target cells was excluded; the exposed medium was then provided to target cells or injected into tumors. PAM was confirmed having the same anti-cancer effect as direct plasma exposure, most importantly PAM can ignore the exposure depth limit and cover a larger injured area that direct plasma exposure can’t achieve. However, PAM was less effective than direct plasma exposure but how exactly lower was remain unknown, in this study the ability of PAM will be affirmed by using direct plasma exposure as a reference in contrast with PAM. Malignant melanoma cells B16-F10, A375, and MeWo cells the most dangerous type of skin cancer cells was used in this study, the reason for choosing skin cancer as target cells are due to malignant melanoma is easily reachable by either direct plasma exposure or PAM. The result shows that the effect of PAM was only briefly lower than direct plasma exposure. Furthermore, NTP has a great effect on B16-F10 and MeWo cells by both direct exposure and PAM. On the other hand, A375 cells show strong resistance to NTP. PAM is a promoting methodology it has the potential to become a new option for skin cancer cure in the future.
論文目次 摘要 I
Abstract III
致謝 IV
Contents V
List of Figures IX
Chapter 1 Introduction 1
1.1 Introduction 1
1.2 Motivation 3
1.3 Background 4
1.3.1 Malignant melanoma. 4
1.3.2 Malignant melanoma therapy 4
1.3.3 Non-thermal micro-plasma system 5
1.4 Objective 7
Chapter 2 Literature survey 8
2.1 Effect of NTP on murine melanoma B16 cells 8
2.1.1 Selective effect of NTP on murine melanoma B16 cells 8
2.1.2 Effect of NTP on murine melanoma B16 cells in vivo assays 11
2.2 Application of plasma device on melanoma cells 12
2.2.1 Effect of plasma device kINPen on melanoma cells 12
2.2.2 Study of dielectric barrier discharge plasma on melanoma cells by using indirect method 13
2.3 Application of Plasma Activated Medium (PAM) 13
2.3.1 PAM in vivo treatment 13
2.3.2 Role of ROS in PAM 15
2.4 Main species induced cell death 16
2.4.1 Main in situ OH radical created by NTP that induced cell death 16
2.4.2 H2O2 does not equal to NTP media 18
2.5 Plasma effect generated reactive species 19
2.5.1 Plasma effect generated reactive oxygen species (ROS) in culture medium 19
2.5.2 Intracellular ROS generated by plasma effect 20
2.6 Cell lines that show resistance to plasma exposure 21
2.7 Plasma jet kINPen based on DIN-specification 91315 22
2.8 Cell apoptosis 23
2.9 Plasma 24
2.9.1 Plasma basic principles 24
2.9.2 Plasma species and effects 25
2.10 Plasma induced ROS/RNS in cell 26
Chapter 3 Materials and methods 28
3.1 Experimental design 28
3.2 Experimental materials 29
3.2.1 Cell culture 29
3.2.2 Preparation of plasma-activated medium(PAM) 30
3.2.3 Non-thermal micro-plasma system 31
3.3 Analysis 32
3.3.1 Fiber optic thermometer 32
3.3.2 Optical emission spectrum 32
3.3.3 ROS detection 33
3.3.4 MTS assay 34
3.3.5 LDH assay 35
3.3.6 Flow cytometry 35
3.3.7 Morphology change after plasma exposure 36
3.4 Statistical analysis 36
Chapter 4 Micro-plasma diagnostic and reactive plasma species 37
4.1 Plasma temperature 37
4.1.1 Discussion for plasma temperature under DIN-specification 91315 38
4.2 Optical emission studies of non-thermal micro-plasma 38
4.2.1 Result of OES scan range: 190-1100 nm 38
4.2.2 Semi-quantitation of species generated by kINPen with He gas 39
4.2.3 Safety of UV radiation under DIN-specification 91315 40
4.2.4 Conclusion for OES scan on plasma radicals and safety of UV radiation 41
4.3 Extracellular ROS concentration change after plasma exposure 42
4.3.1 Discussion for increase in extracellular ROS after plasma exposure 44
Chapter 5 Study of NTP and PAM on malignant melanoma 45
5.1 Cell viability the MTS assay 45
5.1.1 Discussion for cell proliferation rate after plasma exposure 48
5.2 Cell cytotoxicity the LDH assay 49
5.2.1 Discussion for cell cytotoxicity rate after plasma exposure 52
5.3 Flow cytometry 53
5.3.1 B16-F10 cells show a high apoptosis rate after plasma exposure 54
5.3.2 At short plasma exposure time period MeWo cells show resistance 56
5.3.3 Amelanotic melanoma cell line A375 shows strong resistance to plasma exposure 58
5.4 Morphology change after plasma exposure in short time period 60
5.4.1 Cell become rounded after plasma exposure 61
Chapter 6 Conclusion 64
Chapter 7 Perspective 65
Chapter 8 References 66
參考文獻 [1] J. Gay, M. C. García, B. Isla-tejera, A. Rodero-serrano, A. V. García, and J. Ruano, “Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer Characteristics of Cold Atmospheric Plasma.”
[2] J. Raiser and M. Zenker, “Argon plasma coagulation for open surgical and endoscopic applications: state of the art,” Journal of Physics D: Applied Physics, vol. 39, no. 16, p. 3520, 2006.
[3] C. Heslin, D. Boehm, V. Milosavljevic, M. Laycock, P. J. Cullen, and P. Bourke, “Quantitative Assessment of Blood Coagulation by Cold Atmospheric Plasma,” vol. 4, pp. 153–163, 2014.
[4] T. von Woedtke, S. Reuter, K. Masur, and K.-D. Weltmann, “Plasmas for medicine,” Physics Reports, vol. 530, no. 4, pp. 291–320, 2013.
[5] D. Xu et al., “In Situ OH Generation from O2− and H2O2 Plays a Critical Role in Plasma-Induced Cell Death,” Plos One, vol. 10, no. 6, p. e0128205, 2015.
[6] D. Yan et al., “Principles of using Cold Atmospheric Plasma Stimulated Media for Cancer Treatment,” Scientific Reports, vol. 5, no. 1, p. 18339, 2016.
[7] F. Utsumi et al., “Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo,” PLoS ONE, vol. 8, no. 12, pp. 1–10, 2013.
[8] A. Schmidt, S. Bekeschus, T. von Woedtke, and S. Hasse, “Cell migration and adhesion of a human melanoma cell line is decreased by cold plasma treatment,” Clinical Plasma Medicine, 2015.
[9] S. Mohades, M. Laroussi, J. Sears, N. Barekzi, and H. Razavi, “Evaluation of the effects of a plasma activated medium on cancer cells,” vol. 122001, no. 2015, 2017.
[10] G. Daeschlein et al., “Comparison between cold plasma , electrochemotherapy and combined therapy in a melanoma mouse model,” no. 13, pp. 582–586, 2013.
[11] S. Arndt et al., “Cold atmospheric plasma , a new strategy to induce senescence in melanoma cells,” pp. 284–289, 2013.
[12] D. B. Graves, “The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology,” Journal of Physics D: Applied Physics, vol. 45, no. 26, p. 263001, 2012.
[13] G. Isbary et al., “Non-thermal plasma—More than five years of clinical experience,” Clinical Plasma Medicine, vol. 1, no. 1, pp. 19–23, 2013.
[14] S. Aida et al., “MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor,” Cancer Letters, vol. 409, pp. 116–124, 2017.
[15] R. Chicas-sett, I. Morales-orue, and D. Rodriguez-abreu, “Combining radiotherapy and ipilimumab induces clinically relevant radiation- induced abscopal effects in metastatic melanoma patients : A systematic review a Department,” Clinical and Translational Radiation Oncology, 2017.
[16] I. Langmuir, “Oscillations in Ionized Gases,” Proceedings of the National Academy of Sciencesfile, vol. 14, pp. 627–637, 1928.
[17] B. Haertel, T. Von Woedtke, K. Weltmann, and U. Lindequist, “Non-Thermal Atmospheric-Pressure Plasma Possible Application in Wound Healing,” vol. 22, no. 6, pp. 477–490, 2014.
[18] V. Scholtz, J. Pazlarova, H. Souskova, J. Khun, and J. Julak, “Nonthermal plasma — A tool for decontamination and disinfection,” Biotechnology Advances, vol. 33, no. 6, pp. 1108–1119, 2015.
[19] S. Choi et al., “Structural and functional analysis of lysozyme after treatment with dielectric barrier discharge plasma and atmospheric pressure plasma jet.,” Scientific reports, vol. 7, no. 1, p. 1027, Apr. 2017.
[20] G. Daeschlein et al., “In Vitro Susceptibility of Multidrug Resistant Skin and Wound Pathogens Against Low Temperature Atmospheric Pressure Plasma Jet ( APPJ ) and Dielectric Barrier Discharge Plasma ( DBD ),” pp. 175–183.
[21] M. Keidar et al., “Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy,” British Journal of Cancer, vol. 105, no. 9, pp. 1295–1301, 2011.
[22] G. Xu et al., “Effects of atmospheric pressure plasma jet with floating electrode on murine melanoma and fibroblast cells,” Physics of Plasmas, vol. 24, no. 8, 2017.
[23] G. Daeschlein et al., “Enhanced anticancer efficacy by drug chemotherapy and cold atmospheric plasma against melanoma and glioblastoma cell lines in vitro,” IEEE Transactions on Radiation and Plasma Medical Sciences, vol. 2, no. 2, pp. 1–1, 2018.
[24] S. Bekeschus et al., “Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma-Derived Oxidants,” Oxidative Medicine and Cellular Longevity, vol. 2017, 2017.
[25] M. Wang, B. M. Geilich, M. Keidar, and T. J. Webster, “Killing malignant melanoma cells with protoporphyrin IX-loaded polymersome-mediated photodynamic therapy and cold atmospheric plasma,” International Journal of Nanomedicine, vol. 12, pp. 4117–4127, 2017.
[26] M. Yusupov, “Reactive molecular dynamics simulations of oxygen species in a liquid water layer of.”
[27] T. Adachi, H. Tanaka, S. Nonomura, H. Hara, and S. Kondo, “Free Radical Biology and Medicine Plasma-activated medium induces A549 cell injury via a spiral apoptotic cascade involving the mitochondrial – nuclear network,” Free Radical Biology and Medicine, vol. 79, pp. 28–44, 2015.
[28] H. J. Ahn et al., “Targeting cancer cells with reactive oxygen and nitrogen species generated by atmospheric-pressure air plasma,” PLoS ONE, vol. 9, no. 1, 2014.
[29] S. J. Kim and T. H. Chung, “Plasma effects on the generation of reactive oxygen and nitrogen species in cancer cells in-vitro exposed by atmospheric pressure pulsed plasma jets,” Applied Physics Letters, vol. 107, no. 6, 2015.
[30] G. Bauer, “Targeting extracellular ROS signaling of tumor cells,” Anticancer Research, vol. 34, no. 4, pp. 1467–1482, 2014.
[31] D. Trachootham, J. Alexandre, and P. Huang, “Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach?,” Nature Reviews Drug Discovery, vol. 8, no. 7, pp. 579–591, 2009.
[32] K. Torii et al., “Effectiveness of plasma treatment on gastric cancer cells,” Gastric Cancer, vol. 18, no. 3, pp. 635–643, 2015.
[33] R. Sensenig et al., “Non-thermal plasma induces apoptosis in melanoma cells via production of intracellular reactive oxygen species,” Annals of Biomedical Engineering, vol. 39, no. 2, pp. 674–687, 2011.
[34] M. S. Mann et al., “Introduction to DIN-specification 91315 based on the characterization of the plasma jet kINPen® MED,” Clinical Plasma Medicine, vol. 4, no. 2, pp. 35–45, 2016.
[35] C. Physiology, “DNA Damage and Cell Cycle Arrest Induced by Protoporphyrin IX in Sarcoma 180 Cells,” pp. 778–788, 2013.
[36] H. H. and D. Eick, “Mediation of c-myc-induced apoptosis by p53,” vol. 265, pp. 2091–2093, 1994.
[37] M. Ishaq et al., “Atmospheric gas plasma-induced ROS production activates TNF-ASK1 pathway for the induction of melanoma cancer cell apoptosis,” Molecular Biology of the Cell, vol. 25, no. 9, pp. 1523–1531, 2014.
[38] X. Cheng, J. Sherman, W. Murphy, E. Ratovitski, J. Canady, and M. Keidar, “The effect of tuning cold plasma composition on glioblastoma cell viability,” PLoS ONE, vol. 9, no. 5, pp. 1–9, 2014.
[39] C. R. Goodlett, D. Ph, and K. H. Horn, “Mechanisms of Alcohol- Induced Damage to the Developing Nervous System,” vol. 25, no. 3, 2001.
[40] P. J. Ferguson, “Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: A review,” Journal of Otolaryngology, vol. 24, pp. 242–252, 1995.
[41] S. C. R. et al. P. Perego, M. Giarola, “Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems,” Cancer Research, vol. 56, pp. 556–562, 1996.
[42] J. S. G. et al. V. Patel, J. F. Ensley, “Induction of apoptosis in head-and- neck squamous carcinoma cells by gamma-irradiation and bleomycin is p53- independent,” International Jorunal of Cancer, vol. 88, pp. 737–43, 2000.
[43] R. S. et al. A. Paccagnella, G. L. Pappagallo, “Epirubicin, methotrexate and bleomycin in the management of recurrent squamous cell head and neck cancer. A GSTTC randomised phase II study,” European Journal of Cancer, vol. 29, pp. 704–708, 1993.
[44] V. Nehra, “Atmospheric Non-Thermal Plasma Sources,” no. 2, pp. 53–68.
[45] J. W. Fluhr, S. Sassning, O. Lademann, M. E. Darvin, S. Schanzer, and A. Kramer, “In vivo skin treatment with tissue-tolerable plasma influences skin physiology and antioxidant profile in human stratum corneum,” no. 12, pp. 130–134, 2011.
[46] J. Heinlin et al., “Plasma medicine : possible applications in dermatology,” vol. 2010, no. Band 8, pp. 1–9, 2010.
[47] J. Heinlin et al., “Plasma applications in medicine with a special focus on dermatology,” pp. 1–11, 2011.
[48] M. Keidar, “Cold plasma application in cancer therapy,” 2016 IEEE International Conference on Plasma Science (ICOPS), pp. 1–1, 2016.
[49] U. Fantz, “Basics of plasma spectroscopy,” Plasma Sources Science and Technology, vol. 15, no. 4, p. S137, 2006.
[50] K. Datta, S. Sinha, and P. Chattopadhyay, “Reactive oxygen species in health and disease,” National Medical Journal of India, vol. 13, no. 6, pp. 304–310, 2000.
[51] M. V Berridge and A. S. Tan, “Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction.,” Archives of biochemistry and biophysics, vol. 303, no. 2, pp. 474–482, Jun. 1993.
[52] J. A. Barltrop, T. C. Owen, A. H. Cory, and J. G. Cory, “5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans As cell-viability indicat,” Bioorganic & Medicinal Chemistry Letters, vol. 1, no. 11, pp. 611–614, 1991.
[53] S. J. Kim and T. H. Chung, “Cold atmospheric plasma jet-generated RONS and their selective effects on normal and carcinoma cells.,” Scientific reports, vol. 6, p. 20332, Feb. 2016.
[54] M. Vandamme et al., “ROS implication in a new antitumor strategy based on non-thermal plasma,” International Journal of Cancer, vol. 130, no. 9, pp. 2185–2194, 2012.
[55] J. M. Bland and D. G. Altman, “Statistics Notes: Measurement error,” British Medical Journal, vol. 313, p. 744, 1996.
[56] B. B. and D. Habtzghi, “Median of the p Value under the Alternative Hypothesis,” The American Statistician, vol. 56, pp. 202–206, 2002.
[57] 吳知穎, “非熱微電漿引發之 ROS / RNS 對頭頸癌細胞存活之研究,” 成功大學材料科學及工程學系學位論文, 2016.
[58] A. R. Gibson, H. O. McCarthy, A. A. Ali, D. O’Connell, and W. G. Graham, “Interactions of a non-thermal atmospheric pressure plasma effluent with PC-3 prostate cancer cells,” Plasma Processes and Polymers, vol. 11, no. 12, pp. 1142–1149, 2014.
[59] G. E. Conway et al., “Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide,” British Journal of Cancer, vol. 114, no. 4, pp. 435–443, 2016.
[60] H. Tanaka et al., “Plasma-Activated Medium Selectively Kills Glioblastoma Brain Tumor Cells by Down-Regulating a Survival Signaling Molecule, AKT Kinase,” Plasma Medicine, vol. 1, no. 3–4, pp. 265–277, 2011.
論文全文使用權限
  • 同意授權校內瀏覽/列印電子全文服務,於2023-08-01起公開。
  • 同意授權校外瀏覽/列印電子全文服務,於2023-08-01起公開。


  • 如您有疑問,請聯絡圖書館
    聯絡電話:(06)2757575#65773
    聯絡E-mail:etds@email.ncku.edu.tw